Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus VIAGRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus VIAGRA.
ADCIRCA vs VIAGRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels in corpus cavernosum, leading to smooth muscle relaxation and blood flow into the penis.
10 mg orally three times daily.
50 mg orally once as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability. Maximum dosing frequency: once per day.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life approximately 4 hours (range 3–5 hours). No significant accumulation with recommended dosing.
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Renal (approximately 80% as metabolites, 20% as unchanged drug in feces), biliary/fecal (about 13% unchanged in feces). Total clearance 41 L/h.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor